INVEST SECURITIES & INVEST CORPORATE FINANCE ASSISTED BIOPHYTIS FOR THE COMPLETION OF A PRIVATE PLACEMENT OF €3.7M AND THE ARRANGEMENT OF A BOND FINANCING OF €15M
In this transaction, Invest Securities intervened as Bookrunner and Invest Corporate Finance intervened as Adviser for the Transaction.
A biotechnology company listed on the Alternext market of Euronext Paris, Biophytis specialises in diseases related to ageing. This fund raising will allow it to pursue its clinical programme of phase 2B SARA-OBS / SARA-INT, aimed at testing its leading product Sarconeos for the treatment of Sarcopenia.
Description of the financial transaction
Completion of a private placement of €3.7M
Arrangement of a financing by ORNANEBSA that could amount to €15M
This transaction combines a private placement of €3.7M by an increase in capital (of which €1M subscribed by Bracknor Fund Ltd) and a bond financing which can amount to €15M arranged by Bracknor Fund Ltd (bonds repayable or convertible into new or existing shares combined with share warrants).
Executives involved in the transaction
For Invest Corporate Finance: Vincent Déchin, Jean-Emmanuel Vernay, Christine Lambert-Goué, Maxime Bazin
For Invest Securities: Pascal Hadjedj
Biophytis Press release
|BIOPHYTIS is a biotechnology company created in 2006, specialising in diseases related to aging. It develops innovative therapeutic solutions for pathologies without treatment, with a view to restoring muscle and visual functions. BIOPHYTIS thus concentrates its research and development efforts on the fight against macular degeneration related to ageing (DMLA) and muscular dystrophy related to ageing (sarcopenia). For these two particularly invalidating pathologies, the company has proprietary products starting phase 2b: Sarconeos and Macuneos.|
Installed on the campus of Pierre and Marie Curie University (UPMC, 5 Place Jussieu, 75005 Paris), BIOPHYTIS relies on first-class research collaboration with UPMC, in particular the Myology Institute (Institut de Myologie) and the Vision Institute (Institut de la Vision.
BIOPHYTIS is a company listed on the Alternext market of Euronext Paris (ALBPS ; ISIN : FR0012816825). For more information: the internet site.
BIOPHYTIS is eligible for the PEA-SME programme